{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040643","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.760520+00:00","generated_at":"2026-06-11T22:30:56.864505+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Organogenesis Q2 revenue $117.3M (-3% YoY); withdraws FY2023 guidance on Medicare LCDs","bullets":["Net revenue of $117.3M, down 3% YoY from $121.4M; net income $5.3M vs $8.7M.","Adjusted net income $6.1M, adjusted EBITDA $15.4M; both down YoY.","Withdrew FY2023 guidance due to Medicare LCDs from Novitas, First Coast Services, CGS limiting DFU/VLU coverage to only Apligraf and Dermagraft effective Sept 17, 2023.","Cash and equivalents $89.5M, debt $69.0M as of June 30.","Company engaging with relevant parties regarding LCDs; uncertain impact on revenue outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040643","json":"https://secwatch.observer/filing/0000950170-23-040643.json","markdown":"https://secwatch.observer/filing/0000950170-23-040643.md","text":"https://secwatch.observer/filing/0000950170-23-040643.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023040643/0000950170-23-040643-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023040643/orgo-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:30:56.864505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"164bf2853b106ee1a0676344da426c0ec79c75ff","claim":"Organogenesis Holdings Inc. reported the fiscal second quarter ended June 30, 2023 results: revenue $117.3 million, net income $5.3 million, or $0.04 per share, EPS $0.04 per share.","evidence_excerpt":"& Sports Medicine markets, today reported financial results for the second quarter ended June 30th, 2023. Second Quarter 2023 Financial Results Summary: • Net revenue of $117.3 million for the second quarter of 2023, a decrease of $4.1 million compared to net revenue of $121.4 million for the second quarter of 2022. Net revenue for the second quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023040643/0000950170-23-040643-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal second quarter ended June 30, 2023"},{"label":"Revenue","value":"$117.3 million"},{"label":"Net income","value":"$5.3 million, or $0.04 per share"},{"label":"EPS","value":"$0.04 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}